ERS Genomics Limited and Syngene International Successfully Conclude Licensing Agreement
Thursday, October 19, 2023
ERS Genomics, co-founded by Dr. Emmanuelle Charpentier, who was awarded the Nobel Prize in Chemistry in 2020 for her pioneering work in the field of CRISPR/Cas9, provides access to a comprehensive patent portfolio for this groundbreaking technology.
Syngene International Limited, an integrated company offering research, development, and manufacturing services, is well-positioned to utilize the immense potential of CRISPR/Cas9 across various scientific disciplines, including drug discovery, biotechnology, and genomics, on behalf of its clients.
ERS Genomics, expressed his enthusiasm by stating, "We are delighted to partner with Syngene, a global leader in research, development, and manufacturing services. This collaboration promises to unlock new frontiers in genomics research and therapeutic development, empowering their scientific endeavors with the transformative capabilities of CRISPR/Cas9."
"Syngene is dedicated to delivering innovative solutions to our partners worldwide. Our agreement with ERS Genomics underscores this commitment as we gain access to the most advanced CRISPR/Cas9 technology available. This partnership aligns perfectly with our mission to partner with clients to accelerate scientific discovery and support the development of life-changing therapies."
The collaboration between ERS Genomics and Syngene marks a significant addition to India's scientific and commercial landscape and reinforces the nation's growing influence in the global biotechnology and life sciences sector. Both organizations share a focus on driving scientific progress and bringing transformative innovations to the forefront of research and development.
Source: prnewswire.com
